Shelley J Allen

Summary

Affiliation: University of Bristol
Country: UK

Publications

  1. ncbi request reprint TrkAd5: A novel therapeutic agent for treatment of inflammatory pain and asthma
    Judy J Watson
    Molecular Neurobiology Unit, Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, Bristol, UK
    J Pharmacol Exp Ther 316:1122-9. 2006
  2. ncbi request reprint NGF receptor TrkAd5: therapeutic agent and drug design target
    D Dawbarn
    Department of Medicine, University of Bristol, Bristol BS1 3NY, UK
    Biochem Soc Trans 34:587-90. 2006
  3. doi request reprint Human ProNGF: biological effects and binding profiles at TrkA, P75NTR and sortilin
    Oliver Clewes
    Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, University of Bristol, Bristol, UK
    J Neurochem 107:1124-35. 2008
  4. pmc The neurotrophins and their role in Alzheimer's disease
    Shelley J Allen
    Dorothy Hodgkin Building, School of Clinical Sciences, University of Bristol, Bristol BS1 3NY, UK
    Curr Neuropharmacol 9:559-73. 2011
  5. doi request reprint GDNF, NGF and BDNF as therapeutic options for neurodegeneration
    Shelley J Allen
    Dorothy Hodgkin Building, Whitson St, Bristol BS1 3NY, UK
    Pharmacol Ther 138:155-75. 2013
  6. ncbi request reprint Recombinant human nerve growth factor for clinical trials: protein expression, purification, stability and characterisation of binding to infusion pumps
    S J Allen
    Molecular Neurobiology Unit, University Research Centre for Neuroendocrinology Care of the Elderly, University of Bristol, BS2 8HW, Bristol, UK
    J Biochem Biophys Methods 47:239-55. 2001
  7. ncbi request reprint Clinical relevance of the neurotrophins and their receptors
    Shelley J Allen
    University of Bristol, Dorothy Hodgkin Building, Bristol BS1 3NY, UK
    Clin Sci (Lond) 110:175-91. 2006
  8. doi request reprint Targeting nerve growth factor in pain: what is the therapeutic potential?
    Judy J Watson
    University of Bristol, Bristol, UK
    BioDrugs 22:349-59. 2008
  9. ncbi request reprint Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's disease
    S J Allen
    Molecular Neurobiology Unit, Department of Medicine Care of the Elderly, University of Bristol, Bristol Royal Infirmary, Bristol, BS2 8HW, United Kingdom
    Biochem Biophys Res Commun 264:648-51. 1999
  10. ncbi request reprint Neurotrophins and neurodegeneration
    D Dawbarn
    University of Bristol, Bristol Royal Infirmary, Bristol, UK
    Neuropathol Appl Neurobiol 29:211-30. 2003

Collaborators

Detail Information

Publications19

  1. ncbi request reprint TrkAd5: A novel therapeutic agent for treatment of inflammatory pain and asthma
    Judy J Watson
    Molecular Neurobiology Unit, Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, Bristol, UK
    J Pharmacol Exp Ther 316:1122-9. 2006
    ..We conclude that TrkAd5 will prove effective in ameliorating both acute and chronic conditions where nerve growth factor acts as a mediator and suggest a role for its application in vivo as a novel therapeutic...
  2. ncbi request reprint NGF receptor TrkAd5: therapeutic agent and drug design target
    D Dawbarn
    Department of Medicine, University of Bristol, Bristol BS1 3NY, UK
    Biochem Soc Trans 34:587-90. 2006
    ..In addition, TrkAd5 has been shown to be efficacious in preclinical models of inflammatory pain and asthma by the sequestration of excess levels of endogenous NGF, and therefore represents a novel therapeutic agent...
  3. doi request reprint Human ProNGF: biological effects and binding profiles at TrkA, P75NTR and sortilin
    Oliver Clewes
    Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, University of Bristol, Bristol, UK
    J Neurochem 107:1124-35. 2008
    ..Our data show that M-proNGF stimulates TrkA to a lesser degree than NGF, suggesting that in Alzheimer brain the increased proNGF : NGF and p75(NTR) : TrkA ratios may permit apoptotic effects to predominate over neurotrophic effects...
  4. pmc The neurotrophins and their role in Alzheimer's disease
    Shelley J Allen
    Dorothy Hodgkin Building, School of Clinical Sciences, University of Bristol, Bristol BS1 3NY, UK
    Curr Neuropharmacol 9:559-73. 2011
    ..In addition, the possibilities of neurotrophin-based therapeutics are evaluated...
  5. doi request reprint GDNF, NGF and BDNF as therapeutic options for neurodegeneration
    Shelley J Allen
    Dorothy Hodgkin Building, Whitson St, Bristol BS1 3NY, UK
    Pharmacol Ther 138:155-75. 2013
    ..We evaluate these neurotrophic factors as potential short or long-term treatments, weighing up preclinical and clinical results with the possible effects on the underlying neurodegenerative process...
  6. ncbi request reprint Recombinant human nerve growth factor for clinical trials: protein expression, purification, stability and characterisation of binding to infusion pumps
    S J Allen
    Molecular Neurobiology Unit, University Research Centre for Neuroendocrinology Care of the Elderly, University of Bristol, BS2 8HW, Bristol, UK
    J Biochem Biophys Methods 47:239-55. 2001
    ..Tests were also carried out to monitor release of protein from infusion pumps and catheters for intracerebroventricular administration (icv). Initial problems with non-specific binding were overcome using a blocking formula...
  7. ncbi request reprint Clinical relevance of the neurotrophins and their receptors
    Shelley J Allen
    University of Bristol, Dorothy Hodgkin Building, Bristol BS1 3NY, UK
    Clin Sci (Lond) 110:175-91. 2006
    ..Ways in which the neurotrophins, their receptors or agonists/antagonists may act therapeutically are discussed...
  8. doi request reprint Targeting nerve growth factor in pain: what is the therapeutic potential?
    Judy J Watson
    University of Bristol, Bristol, UK
    BioDrugs 22:349-59. 2008
    ..Other possible future therapies examined in this review include small-molecule TrkA antagonists, which target either the extracellular NGF binding domain of TrkA or its intracellular tyrosine kinase domain...
  9. ncbi request reprint Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's disease
    S J Allen
    Molecular Neurobiology Unit, Department of Medicine Care of the Elderly, University of Bristol, Bristol Royal Infirmary, Bristol, BS2 8HW, United Kingdom
    Biochem Biophys Res Commun 264:648-51. 1999
    ..This may have important consequences for the neurotrophic support of vulnerable neurons in AD...
  10. ncbi request reprint Neurotrophins and neurodegeneration
    D Dawbarn
    University of Bristol, Bristol Royal Infirmary, Bristol, UK
    Neuropathol Appl Neurobiol 29:211-30. 2003
    ....
  11. ncbi request reprint In vitro studies of membrane protein folding
    P J Booth
    Department of Biochemistry, School of Medical Sciences, University Walk, Bristol, UK
    Crit Rev Biochem Mol Biol 36:501-603. 2001
    ..With this in mind, we also cover some relevant properties of model, lipid-bilayer systems...
  12. ncbi request reprint Can we identify the forces that drive the folding of integral membrane proteins?
    P J Booth
    Department of Biochemistry, University of Bristol, University Walk, Bristol BS8 1TD, UK
    Biochem Soc Trans 29:408-13. 2001
    ..These are generic properties of the bilayer that can be achieved with simple mixtures of many types of biological lipid and seem to be important in vivo...
  13. ncbi request reprint Identification and structure of the nerve growth factor binding site on TrkA
    A G Robertson
    Molecular Neurobiology Unit, URCN, Bristol, BS2 8HW, United Kingdom
    Biochem Biophys Res Commun 282:131-41. 2001
    ..We also present the three-dimensional structure of the TrkAIg(2) domain in a new crystal form, refined to 2.0 A resolution...
  14. ncbi request reprint Identification of syntaxin 1A as a novel binding protein for presenilin-1
    S K Smith
    Molecular Neurobiology Unit, Department of Medicine Care of the Elderly, University of Bristol, Bristol, BS2 8HW, UK
    Brain Res Mol Brain Res 78:100-7. 2000
    ..In vitro experiments confirm the two-hybrid results suggesting that PS1 binds syntaxin under physiological conditions...
  15. ncbi request reprint Production of an activated form of Bacillus stearothermophilus L-2-hydroxyacid dehydrogenase by directed evolution
    S J Allen
    Molecular Recognition Centre, Department of Biochemistry, School of Medical Sciences, University of Bristol, University Walk, Bristol BS8 1TD, UK
    Protein Eng 13:5-7. 2000
    ..What is significant is the activation of bsLDH by a subtle long range event produced by the 'blind' directed evolution approach...
  16. ncbi request reprint alpha- and beta-secretase: profound changes in Alzheimer's disease
    Susan J Tyler
    Molecular Neurobiology Unit, URCN Care of the Elderly University of Bristol, Bristol Royal Infirmary, Bristol, UK
    Biochem Biophys Res Commun 299:373-6. 2002
    ..Eighty percent of Alzheimer brains examined had an increase in beta-secretase, a decrease in alpha-secretase, or both; which may account for the means by which the majority of people develop Alzheimer's disease...
  17. ncbi request reprint Stepwise, non-adherent differentiation of human pluripotent stem cells to generate basal forebrain cholinergic neurons via hedgehog signaling
    Lucy A Crompton
    Henry Wellcome Laboratory for Integrative Neuroscience and Endocrinology, School of Clinical Sciences, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY, UK
    Stem Cell Res 11:1206-21. 2013
    ..In conclusion, this work provides a renewable source of human functional bfCNs applicable for studying AD specifically in the cholinergic system, and also provides a model of the key embryonic events in human bfCN development. ..
  18. ncbi request reprint A discrete domain of the human TrkB receptor defines the binding sites for BDNF and NT-4
    Ruth L Naylor
    University Research Centre for Neuroendocrinology Care of the Elderly, Bristol Royal Infirmary, Bristol, BS2 8HW, United Kingdom
    Biochem Biophys Res Commun 291:501-7. 2002
    ..It is hoped that the understanding of specific interactions will allow design of small molecule neurotrophin mimetics...
  19. ncbi request reprint Premorbid effects of APOE on synaptic proteins in human temporal neocortex
    Seth Love
    Department of Neuropathology, University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol BS16 1LE, UK
    Neurobiol Aging 27:797-803. 2006
    ..01). APOE influences the concentration of synaptic proteins in normal superior temporal cortex and may thereby affect the response to injury, and the risk and outcome of a range of neurologic diseases...